Improvement in Palivizumab Administration Prior to Discharge for Hospitalized Infants with Hemodynamically Significant Congenital Heart Disease: A Quality Improvement Initiative-Reference-Cited by-同舟云学术

Improvement in Palivizumab Administration Prior to Discharge for Hospitalized Infants with Hemodynamically Significant Congenital Heart Disease: A Quality Improvement Initiative

Published:2023-05-05 Issue: Volume: Page:
ISSN:0172-0643
Container-title:Pediatric Cardiology
language:en
Short-container-title:Pediatr Cardiol

Author:

Jones Andrea L.^ORCID,Campbell Matthew J.,Abernathy Brittany,Neubert Stephanie,Hager Alyssa,Collier Hailey,Ramsey Evan Zachary,Simon Anna,Schachtner Susan,Natarajan Shobha

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Pediatrics, Perinatology and Child Health

Link

https://link.springer.com/content/pdf/10.1007/s00246-023-03163-4.pdf

Reference21 articles.

1. Shi T et al (2021) Risk factors for RSV associated acute lower respiratory infection poor outcome and mortality in young children: a systematic review and meta-analysis. J Infect Dis 226:S10–S16

2. Hall CB et al (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360(6):588–598

3. Resch B, Michel-Behnke I (2013) Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab. Curr Opin Cardiol 28(2):85–91

4. Simon A et al (2007) Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr 166(12):1273–1283

5. Wegzyn C et al (2014) Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infect Dis Ther 3(2):133–158